Drug intelligence / Profile preview

TGC

Development stage
Unknown
Lead developer
Lynk Biotechnologies
Modality
Small Molecules
Administration
Topical, Transdermal
01

Overview

TGC (Transdermal Glucosamine Cream) is a topical formulation developed by Lynk Biotechnologies for the treatment of knee osteoarthritis. It utilizes a proprietary transdermal delivery technology to deliver glucosamine sulfate directly through the skin to the synovial fluid of the affected joint. Glucosamine is a naturally occurring amino sugar that serves as a critical building block for the synthesis of glycosaminoglycans and proteoglycans, which are essential components of the cartilage matrix. By delivering the active ingredient topically, TGC aims to provide targeted relief and support cartilage health while bypassing the gastrointestinal metabolism and potential systemic side effects associated with oral glucosamine administration. The product is available in various concentrations, including a 10% high-strength version.

Brand names
TGC
Other names
Transdermal Glucosamine CreamTGC High StrengthLynk Glucosamine Cream
02

Targets

Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on TGC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TGC.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call